Two stages exist. An internal appeal goes to the plan and must be filed within 180 days of the denial notice. If that fails, an independent external review must be requested within four months. What usually decides these cases is the indication: this drug is approved for type 2 diabetes, so an appeal built on weight-loss evidence is arguing the wrong point.
Decide what is being challenged before writing anything
Three things get confused. A grievance is a complaint about service, and it changes no coverage decision. An exception request asks a plan to cover something outside its normal rules, such as a drug absent from the list or a use outside the label. An appeal challenges a decision the plan has already issued. HealthCare.gov describes an appeal as a request to review a decision that denies a benefit or payment, and the appeal rights described here attach to that.
Some outcomes are not appealable in any useful sense. When the benefit category was excluded from the contract before anyone enrolled, there is no medical judgment for a reviewer to overturn. HealthCare.gov lists benefit exclusion among the reasons a plan may issue a denial, and separates it from determinations about medical necessity or experimental status, which are the ones external reviewers are empowered to revisit.
Stage one: the internal appeal
The member completes the plan’s forms, or writes with name, claim number and insurance ID, and submits anything additional the insurer should consider, including a letter from the prescriber. The federal deadline is 180 days from receiving notice of the denial. A state Consumer Assistance Program can file on a member’s behalf. In an urgent health situation, an external review can be requested at the same time as the internal appeal rather than after it.
Keep copies of everything: the Explanation of Benefits or letters showing what was denied, the appeal request itself, any documents sent in support, and dated notes from phone calls including the name and title of whoever answered. Originals stay with the member and copies go to the insurer.
Stage two: independent external review
A written request for external review must be filed within four months of the final determination notice. The reviewer either upholds the plan or decides for the member, and the insurer is required by law to accept that decision. Standard external reviews are decided no later than 45 days after the request is received. Insurance companies in every state must offer a process meeting federal consumer protection standards, and where a state process meets or exceeds them, the state’s process applies.
One current caveat is worth checking against the notice in hand. HealthCare.gov posts an advisory for residents of Alabama, Florida, Georgia, Texas, Wisconsin and United States territories other than Puerto Rico whose plan uses the HHS-administered Federal External Review Process: as of July 1, 2026 that process is temporarily unavailable, and the department has said it will provide information about extending deadlines. Plans not using it give filing instructions in their own notice.
The indication is the argument
The DailyMed label for this product describes one use, an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The tirzepatide product labeled for chronic weight management is Zepbound, which also carries an indication for moderate to severe obstructive sleep apnea in adults with obesity, supported by a randomized trial in adults with obesity and moderate to severe disease.
That splits appeals into two very different exercises. Where type 2 diabetes is documented, the appeal is evidentiary: produce the diagnosis with its date, the glycemic values, the treatment history and the prescriber’s reasoning, and the request sits squarely inside the label. Where the treatment goal is weight, an appeal asking the plan to pay for a diabetes product is asking for an off-label exception, and the stronger path is usually a fresh request for the product whose label matches the goal.
The two stages at a glance
| Stage | Deadline to file | Decision window | What tends to change the outcome |
|---|---|---|---|
| Internal appeal | 180 days from the denial notice | Set by federal rules for the request type | Records that answer the criteria actually applied |
| External review | Four months from the final determination | No later than 45 days for standard reviews | A medical judgment question the reviewer can revisit |
| Exception request | Any time, before a denial exists | Set by the plan’s pharmacy process | Alternatives documented as tried or unsuitable |
| Grievance | Any time | Not a coverage timeline | Nothing; it does not reverse a decision |
An appeal needs something the first request did not have
Resubmitting the same file rarely works, because the same reviewer criteria produce the same result. What moves a case is new material: laboratory results that were pending at first submission, a corrected diagnosis code, chart notes showing the duration and outcome of prior therapy, or a letter that names the criteria and answers them line by line. Where the plan applied criteria for a use the label does not describe, saying so directly is more effective than adding volume.
Treatment while the appeal runs
The self-pay market a member weighs against coverage is not a single price but several. Eli Lilly lists a branded rate through LillyDirect, while independent telehealth providers such as Henry Meds, Ro and HealthRX keep public Mounjaro pages that spell out what each monthly offer includes. Looking at a handful together is what tells a member whether a given quote is ordinary or an outlier.
Appeals take weeks and can take months once external review is involved, and interruption is not neutral with this class, since published maintenance data show weight returning after treatment stops. A parallel cash arrangement during that window is a hedge, not a surrender, and it does not weaken the appeal.
Prices in that market are not comparing like with like. Manufacturer channels publish rates for the branded products, and supervised telehealth practices including Ro, Hims and Hers and FormBlends publish monthly figures for compounded semaglutide or tirzepatide. Compounded preparations are prepared by pharmacies rather than approved by the FDA, which has not evaluated them for safety, effectiveness or manufacturing quality.
Frequently asked questions
Can someone file on the member’s behalf?
Yes. A prescriber or another representative can file, and a state Consumer Assistance Program can file an internal appeal for a member. Plans generally require a signed authorization naming that person, so keep a copy of whatever form is signed, because a missing authorization stalls otherwise valid appeals.
Does an external reviewer have to follow the plan’s own criteria?
An independent reviewer examines denials involving medical judgment, including determinations that a treatment is experimental or investigational. It weighs the plan’s rules against the clinical record rather than simply applying them, and its decision binds the insurer by law.
What if the plan misses its own deadline?
Missed deadlines matter and should be documented with dates and names. Federal rules set outer limits for notices and decisions, so a written record of when the request went in and when nothing came back is the material that supports escalation to a state insurance regulator.
Is a new diagnosis better handled as an appeal or a new request?
Usually a new request. If type 2 diabetes was diagnosed after the denial, the earlier decision was made on a different record, and a fresh submission with the current diagnosis is cleaner and faster than persuading an appeal panel to consider facts that did not exist at the time.
